| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7851506 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
| US8324275 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
| US8263650 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
| US8859619 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
| US8952062 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
| US9539330 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
|
US7851506 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
|
US8263650 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
|
US8324275 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
|
US9539330 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
|
US8952062 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
|
US8859619 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
| US7262219 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jul, 2020
(3 years ago) | |
| US6780889 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jul, 2020
(3 years ago) | |
|
US7262219 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jan, 2021
(3 years ago) | |
|
US6780889 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jan, 2021
(3 years ago) | |
| US8731963 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
| US8457988 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
| US8589182 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
| US7895059 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
|
US8589182 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(10 months ago) | |
|
US7895059 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(10 months ago) | |
|
US8731963 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(10 months ago) | |
|
US8457988 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(10 months ago) | |
| US7668730 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(a month from now) | |
| US7765106 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(a month from now) | |
| US7765107 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(a month from now) | |
|
US7765106 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(7 months from now) | |
|
US7765107 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(7 months from now) | |
|
US7668730 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(7 months from now) | |
| US9050302 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US8772306 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US9486426 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10864181 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US11253494 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10213400 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
|
US9486426 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10864181 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US9050302 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US11253494 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10213400 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US8772306 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
Xyrem is owned by Jazz Pharms.
Xyrem contains Sodium Oxybate.
Xyrem has a total of 42 drug patents out of which 24 drug patents have expired.
Expired drug patents of Xyrem are:
- US7851506
- US8324275
- US8263650
- US8859619
- US8952062
- US9539330
- US7851506*PED
- US8263650*PED
- US8324275*PED
- US9539330*PED
- US8952062*PED
- US8859619*PED
- US7262219
- US6780889
- US7262219*PED
- US6780889*PED
- US8731963
- US8457988
- US8589182
- US7895059
- US8589182*PED
- US7895059*PED
- US8731963*PED
- US8457988*PED
Xyrem was authorised for market use on 17 July, 2002.
Xyrem is available in solution;oral dosage forms.
Xyrem can be used as a method of treating a patient with a prescription drug using an exclusive computer database in a computer system for distribution, a method to control abuse of a sensitive drug by controlling with a computer processor the distribution of the sensitive drug via an exclusivity central pharmacy that maintains a central database, method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium, method of treating excessive daytime sleepiness in patients with narcolepsy, method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered., method of treating cataplexy in patients with narcolepsy, method of treating patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered, method of treating a patient with a prescription drug using a computer database in a computer system for distribution.
The generics of Xyrem are possible to be released after 15 September, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-231) | Oct 26, 2025 |
| Pediatric Exclusivity(PED) | Apr 26, 2026 |
| New Patient Population(NPP) | Oct 26, 2021 |
| Orphan Drug Exclusivity(ODE) | Nov 18, 2012 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 17 July, 2002
Treatment: Method of treating excessive daytime sleepiness in patients with narcolepsy; Method of treating cataplexy in patients with narcolepsy; Method of treating a patient with a prescription drug using a com...
Dosage: SOLUTION;ORAL
XYREM family patents
